多巴丝肼联合普拉克索治疗帕金森病的临床疗效

The Clinical Effect of Benserazide and Pramipexole in Treatment of Parkinson's Disease

目的:探讨多巴丝肼联合普拉克索治疗帕金森病的临床疗效。方法:以入院病历号为编号,根据随机数字表,将106名帕金森病患者随机分成分两组,每组53例。治疗过程中,给予多巴丝肼片治疗的患者记为对照组(53例);给予多巴丝肼联合普拉克索治疗的患者记为观察组(53例)。连续治疗12周,观察两组患者总疗效、UPDRS评分、HAMD评分及不良反应,探讨其临床治疗价值。结果:1观察组总有效率明显高于对照组总有效率,差异有统计学意义(P<0.05)。2与治疗前相比,治疗后两组UPDRS各项评分均明显改善(P<0.05),且观察组UPDRS各项评分明显优于对照组(P<0.05)。3与治疗前相比,治疗后两组HAMD评分均明显改善(P<0.05),且观察组HAMD评分明显优于对照组(P<0.05)。结论:多巴丝肼联合普拉克索治疗帕金森病疗效确切,安全可靠,值得临床推广应用。

Objective： To investigate the clinical effect of Benserazide and pramipexole in treatment of Parkinson＇s disease. Methods： To the hospital medical record number as number, according to the random number table, 106 patients with Parkinson disease were randomly divided into two groups, 53 cases in each group. The patients in control group were treated with Benserazide tablets and the patients in observation group were given Benserazide combined with pramipexole. After 12 weeks treatment, the total efficacy, UPDRS score, HAMD score and adverse reactions of the two groups were observed, and the clinical value of the treatment was discussed. Results： ①The total effective rate in the observation group was significantly higher than that in the control group （P 〈 0.05）. ②Compare with before treatment, the UPDRS score was better in two groups after treatment （P〈0.05）; after treatment, the UPDRS score in the observation group was better than that of the control group（P〈0.05）. ③Compare with before treatment, the HAMD score was better in two groups after treatment （P〈0.05）; after treatment, the HAMD score in the observation group was better than that of the control group （P〈0.05）. Conclusions： Benserazide combined with pramipexole in the treatment of Parkinson＇s disease has exact curative effect with good safety and reliablity, worthy of clinical application.